Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection.
about
Chlamydia trachomatis Genital Infections.A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.Chlamydial protease-like activity factor--insights into immunity and vaccine developmentFrancisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice.Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigsHeat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challengeImmunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection.TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccinesCPAF: a Chlamydial protease in search of an authentic substrate.Induction of protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial immunodominant antigen macrophage infectivity potentiator.Use of a Guinea pig-specific transcriptome array for evaluation of protective immunity against genital chlamydial infection following intranasal vaccination in Guinea pigs.Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.Antibody signature of spontaneous clearance of Chlamydia trachomatis ocular infection and partial resistance against re-challenge in a nonhuman primate trachoma model.Chlamydia muridarum infection associated host MicroRNAs in the murine genital tract and contribution to generation of host immune response.A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge.Tumor necrosis factor alpha production from CD8+ T cells mediates oviduct pathological sequelae following primary genital Chlamydia muridarum infectionVaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challengeTumor Necrosis Factor (TNF) Receptor Superfamily Member 1b on CD8+ T Cells and TNF Receptor Superfamily Member 1a on Non-CD8+ T Cells Contribute Significantly to Upper Genital Tract Pathology Following Chlamydial InfectionFrequency of Chlamydia trachomatis-specific T cell interferon-γ and interleukin-17 responses in CD4-enriched peripheral blood mononuclear cells of sexually active adolescent females.Immunization with dendritic cells pulsed ex vivo with recombinant chlamydial protease-like activity factor induces protective immunity against genital chlamydiamuridarum challengeMRI as a Novel In Vivo Approach for Assessing Structural Changes of Chlamydia Pathology in a Mouse Model.Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach.Quantitative In Vivo Detection of Chlamydia muridarum Associated Inflammation in a Mouse Model Using Optical ImagingRottlerin inhibits chlamydial intracellular growth and blocks chlamydial acquisition of sphingolipids from host cells.The contribution of Chlamydia-specific CD8⁺ T cells to upper genital tract pathology.Immunostimulatory DNA as a vaccine adjuvant.Vaccines for Chlamydia infections of the female genital tract.Identifying catalytic residues in CPAF, a Chlamydia-secreted protease.Towards a Chlamydia trachomatis vaccine: how close are we?Murine MicroRNA-214 regulates intracellular adhesion molecule (ICAM1) gene expression in genital Chlamydia muridarum infection.In vivo whole animal body imaging reveals colonization of Chlamydia muridarum to the lower genital tract at early stages of infection.
P2860
Q30235030-30D8AFD0-3FC7-4CB3-AB76-B71DEB6E434EQ30558032-260BD7DD-360B-4BF9-951D-37EC6B34674FQ33584064-B4DDF94D-8F02-4FA8-B2DA-8DA718EB12B2Q33627084-260726D5-EC6A-4D61-B8E1-86CFBAB4AB75Q33740057-66E1DCEE-DAB4-46D6-BC85-45C99ACCF813Q33757531-1AD7EA7C-6783-4BF6-BF56-CB003A5B26F0Q34119450-7D39522D-5EF4-4A7F-AC7A-000B49359877Q34177368-AF36547F-B526-40AD-A5AC-57F8EC442200Q34290717-7E8EB2AE-595C-48EF-9BF7-9DAA7B5C5DC4Q34372321-CCC7C783-7A07-424F-A31A-40C2A39EFD10Q34445366-FF7EBAFE-4897-48EE-9C08-5548806E2294Q34680475-AC766F46-2196-48B3-A938-933A24AA6170Q34739969-E0DBF379-F043-415C-BDAE-0FC976DCA4A4Q34759137-9FF168E8-5EA2-4A88-9320-199355CC7583Q35169667-C19E9882-3D35-4CBC-A4B9-E025B11B1A2CQ35214742-94E0DACD-E250-46D9-87E0-BCD71FE8C80BQ35329016-0769C88B-5D8E-458B-8AFF-354BF240BEA0Q35546561-D9D211BE-0556-43A8-901F-1A985EDFA65AQ35837314-A5B467E8-1ACA-47B2-8CD4-EDD60E844FE7Q35861640-C3A12074-CC75-42FD-B2AC-26C44254AA30Q35927600-62AF23CA-EF1D-43B9-9244-9D485A33BD5DQ36088710-45BDDE4C-AFC3-41EB-AE10-7AE9502E7A0AQ36314065-50FF347C-C559-4A4A-B3CA-6568F6662775Q36339573-5C633DD0-5C16-42FB-8F59-D0D13977F103Q36483003-C4734C66-2CCB-49C8-9C99-95464BD6CCB5Q36563801-D5789D02-3693-46CC-8A97-5BE6D2B207A7Q36968274-A241EC46-9F60-460A-997D-F70197FA0441Q37071155-634C90DA-ED2C-4BF8-BFFD-430D7D966A23Q37401433-3E273CB1-F68B-4527-A1FF-D56B9E606FFFQ37820669-7E1AA719-CE69-4545-88A8-47DCFFD32159Q37841127-F3E57B4F-5357-4A18-BFD3-F40D71E43D65Q37844533-5F348157-F182-4881-B56B-3C1E66260ED3
P2860
Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 February 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intranasal immunization with c ...... Chlamydia muridarum infection.
@en
Intranasal immunization with c ...... Chlamydia muridarum infection.
@nl
type
label
Intranasal immunization with c ...... Chlamydia muridarum infection.
@en
Intranasal immunization with c ...... Chlamydia muridarum infection.
@nl
prefLabel
Intranasal immunization with c ...... Chlamydia muridarum infection.
@en
Intranasal immunization with c ...... Chlamydia muridarum infection.
@nl
P2093
P2860
P1433
P1476
Intranasal immunization with c ...... Chlamydia muridarum infection.
@en
P2093
Ashlesh K Murthy
Bernard P Arulanandam
Guangming Zhong
M Neal Guentzel
Madhulika Jupelli
P2860
P304
P356
10.1016/J.VACCINE.2007.02.010
P407
P577
2007-02-23T00:00:00Z